<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="review-article"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">J Vasc Bras</journal-id><journal-id journal-id-type="iso-abbrev">J Vasc Bras</journal-id><journal-id journal-id-type="publisher-id">jvb</journal-id><journal-title-group><journal-title>Jornal Vascular Brasileiro</journal-title></journal-title-group><issn pub-type="ppub">1677-5449</issn><issn pub-type="epub">1677-7301</issn><publisher><publisher-name>Sociedade Brasileira de Angiologia e de Cirurgia Vascular (SBACV)</publisher-name></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">40012967</article-id><article-id pub-id-type="pmc">PMC11864779</article-id><article-id pub-id-type="publisher-id">jvbAR20240098_PT</article-id><article-id pub-id-type="other">01201</article-id><article-id pub-id-type="doi">10.1590/1677-5449.202400982</article-id><article-categories><subj-group subj-group-type="heading"><subject>Study Protocol</subject></subj-group></article-categories><title-group><article-title>Topical oxybutynin deodorant for axillary hyperhidrosis: a topic or a systemic effect? Rationale and design of the phase II today trial</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0003-3272-2940</contrib-id><name><surname>Neves</surname><given-names>Samantha</given-names></name><role>conception and design</role><role>analysis and interpretation</role><role>data collection</role><role>writing the article</role><role>final approval of the article</role><role>statistical analysis</role><role>overall responsibility</role><xref rid="aff0100" ref-type="aff">1</xref><xref ref-type="bio" rid="d67e43">*</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0009-0001-1396-9553</contrib-id><name><surname>Volpiani</surname><given-names>Giuliano Giova</given-names></name><role>writing the article</role><role>final approval of the article</role><xref rid="aff0100" ref-type="aff">1</xref><xref ref-type="bio" rid="d67e55">*</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0003-2627-1821</contrib-id><name><surname>Paganotti</surname><given-names>Alexia</given-names></name><role>data collection</role><xref rid="aff0100" ref-type="aff">1</xref><xref ref-type="bio" rid="d67e66">*</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0002-6978-2798</contrib-id><name><surname>Menegueti</surname><given-names>Felipe</given-names></name><role>data collection</role><xref rid="aff0100" ref-type="aff">1</xref><xref ref-type="bio" rid="d67e77">*</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0009-0001-6008-589X</contrib-id><name><surname>Boix</surname><given-names>Ricardo Sanchez</given-names></name><role>data collection</role><xref rid="aff0100" ref-type="aff">1</xref><xref ref-type="bio" rid="d67e88">*</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0001-6352-4408</contrib-id><name><surname>Caffaro</surname><given-names>Roberto Augusto</given-names></name><role>conception and design</role><xref rid="aff0100" ref-type="aff">1</xref><xref ref-type="bio" rid="d67e99">*</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0003-2754-8618</contrib-id><name><surname>dos Santos</surname><given-names>Vanessa Prado</given-names></name><role>writing the article</role><role>final approval of the article</role><xref rid="aff0200" ref-type="aff">2</xref><xref ref-type="bio" rid="d67e111">*</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0002-5735-1333</contrib-id><name><surname>Ramacciotti</surname><given-names>Eduardo</given-names></name><role>conception and design</role><role>analysis and interpretation</role><role>critical revision of the article</role><role>final approval of the article</role><xref rid="aff0300" ref-type="aff">3</xref><xref rid="aff0400" ref-type="aff">4</xref><xref ref-type="bio" rid="d67e125">*</xref></contrib><aff id="aff0100">
<label>1</label>
<institution content-type="original">Irmandade Santa Casa de Miseric&#x000f3;rdia de S&#x000e3;o Paulo, S&#x000e3;o Paulo, SP, Brasil.</institution>
</aff><aff id="aff0200">
<label>2</label>
<institution content-type="original">Universidade Federal da Bahia, Faculdade de Medicina da Bahia, Salvador, BA, Brasil.</institution>
</aff><aff id="aff0300">
<label>3</label>
<institution content-type="original">Science Valley Research Institute, S&#x000e3;o Paulo, SP, Brasil.</institution>
</aff><aff id="aff0400">
<label>4</label>
<institution content-type="original">Loyola University Medical Center, Hemostasis &#x00026; Thrombosis Research Laboratories, Maywood, IL, EUA.</institution>
</aff></contrib-group><author-notes><fn fn-type="COI-statement"><p>Conflicts of interest: No conflicts of interest declared concerning the publication of this article.</p></fn><fn fn-type="other"><p>Ethics committee approval: The Brazilian Ministry of Health&#x02019;s National Research Ethics Commission (CONEP - Comiss&#x000e3;o Nacional de &#x000c9;tica em Pesquisa) approved the study protocol (CAAE 30283520.0.0000.5479; decision 3.978.439).</p></fn><corresp id="c0100"><bold>Correspondence</bold> Samantha Neves Irmandade Santa Casa de Miseric&#x000f3;rdia de S&#x000e3;o Paulo Rua Dr. Sodr&#x000e9;, 122, conjunto 41 - Vila Nova Concei&#x000e7;&#x000e3;o CEP 03545-110 - S&#x000e3;o Paulo (SP), Brasil Tel.: +55 (11) 94524-0889 E-mail: <email>samanthaneves74@gmail.com</email>
</corresp></author-notes><pub-date date-type="pub" publication-format="electronic"><day>21</day><month>2</month><year>2025</year></pub-date><pub-date date-type="collection" publication-format="electronic"><year>2025</year></pub-date><volume>24</volume><elocation-id>e20240098</elocation-id><history><date date-type="received"><day>25</day><month>6</month><year>2024</year></date><date date-type="accepted"><day>23</day><month>10</month><year>2024</year></date></history><permissions><copyright-statement>Copyright&#x000a9; 2025 The authors.</copyright-statement><copyright-year>2025</copyright-year><copyright-holder>The authors.</copyright-holder><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><abstract><title>Abstract</title><p>Anticholinergics have been shown to enhance quality of life and reduce sweat in patients with hyperhidrosis. However, it remains unclear whether topical application specifically exerts local or systemic effects. This study&#x02019;s primary aim is to assess topical oxybutynin&#x02019;s impact on axillary hyperhidrosis. Twenty patients will be randomized into three groups. Group A will receive 2.5 mg of oral oxybutynin from day 1 to day 35 (on a variable frequency regimen). Group B will be administered a topical placebo for 35 days and Group C will receive a 10% oxybutynin topical spray, to be used twice daily for 35 days. The primary efficacy outcome will be the evaluation of the effectiveness of topical oxybutynin spray in treating hyperhidrosis. The TODAY trial will generate high-quality evidence on the effects of topical oxybutynin, assessing whether its impact is local or systemic in patients with axillary hyperhidrosis.</p></abstract><kwd-group><title>Keywords: </title><kwd>hyperhidrosis</kwd><kwd>oxybutynin</kwd><kwd>anticholinergic</kwd><kwd>axillary hyperhidrosis</kwd></kwd-group><counts><fig-count count="6"/><table-count count="2"/><equation-count count="0"/><ref-count count="17"/></counts></article-meta></front><body><sec sec-type="intro"><title>INTRODUCTION</title><p>Hyperhidrosis (HH) is a condition characterized by excessive sweating, exceeding the level necessary for regulation of body temperature.<sup><xref rid="B001" ref-type="bibr">1</xref></sup> It affects approximately 15.3 million individuals in North America.<sup><xref rid="B002" ref-type="bibr">2</xref></sup> The etiology of primary HH remains poorly defined, but it is believed that it involves hyperactivity of the sympathetic nervous system caused by genetic predispositions.<sup><xref rid="B003" ref-type="bibr">3</xref></sup> Hyperhidrosis has a significant impact on quality of life (QoL) and is associated with similar social and professional stigma to chronic conditions such as severe psoriasis. Individuals with HH also have higher rates of depression and anxiety.<sup><xref rid="B004" ref-type="bibr">4</xref></sup> Primary HH, also known as idiopathic HH, accounts for around 90% of HH cases and the armpits are the most affected area.<sup><xref rid="B003" ref-type="bibr">3</xref></sup> This form of HH generally starts in adolescence and tends to worsen over the years.<sup><xref rid="B005" ref-type="bibr">5</xref>-<xref rid="B007" ref-type="bibr">7</xref></sup></p><p>Current treatment options for HH include video-assisted thoracoscopic sympathectomy (VATS), botulinum toxin injections, a range of topical treatments, and oral anticholinergics, but efficacy is variable and they can cause significant side effects.<sup><xref rid="B008" ref-type="bibr">8</xref>,<xref rid="B009" ref-type="bibr">9</xref></sup> A long-term study involving 1,685 cases of primary HH treated with oral oxybutynin demonstrated improved quality of life and reduced HH severity, as measured by the hyperhidrosis disease severity scale (HDSS), although 24.9% of the patients experienced intense dry mouth.<sup><xref rid="B010" ref-type="bibr">10</xref></sup> There are a limited number of reports of use of topical anticholinergics and of topical glycopyrrolate in the form of pads and creams, and of oxybutynin in gel form, which demonstrated efficacy.<sup><xref rid="B011" ref-type="bibr">11</xref>-<xref rid="B014" ref-type="bibr">14</xref></sup></p></sec><sec><title>BACKGROUND AND STUDY OBJECTIVES</title><p>Topical oxybutynin spray is easier to use, but has not previously been tested. The benefit of using an oxybutynin 10% spray for axillary HH would be expected to accrue from its limited systemic effects, which could reduce the sympathomimetic side effects observed with oral anticholinergic and so potentially improve adherence to treatment, improving both QoL questionnaire scores<sup><xref rid="B015" ref-type="bibr">15</xref></sup> and HDSS scores.<sup><xref rid="B016" ref-type="bibr">16</xref></sup></p><p>This phase II trial will assess the efficacy of a topical oxybutynin 10% spray applied twice a day, in comparison to a placebo and to oral oxybutynin in patients with axillary HH.</p></sec><sec sec-type="methods"><title>METHODS</title><sec><title>Study design</title><p>TODAY (ClinicalTrials.gov: NCT05102396) is a pragmatic, randomized trial, conducted by academic investigators from multiple centers. The name is an acronym derived from the title &#x0201c;<bold><italic toggle="yes"><underline>TO</underline></italic></bold>
<italic toggle="yes">pical oxybutynin for hyperhi</italic>
<bold><italic toggle="yes"><underline>D</underline></italic></bold>
<italic toggle="yes">rosis:</italic>
<bold><italic toggle="yes"><underline>A</underline></italic></bold>
<italic toggle="yes">topic or s</italic>
<bold><italic toggle="yes"><underline>Y</underline></italic></bold>
<italic toggle="yes">stemic effect</italic>&#x0201d;.</p><p>The study design is Prospective Randomized Open Blinded Endpoint (PROBE) and approximately 21 patients on anticholinergic treatment with a confirmed diagnosis of HH will be recruited, as illustrated in <xref rid="gf0100" ref-type="fig">Figure 1</xref>.</p><fig position="float" fig-type="figure" id="gf0100"><label>Figure 1</label><caption><title>Study design of the TODAY clinical trial (topical oxybutynin for axillary hyperhidrosis).</title></caption><graphic xlink:href="jvb-24-e20240098-g01-en" position="float"/></fig><p>The TODAY trial is part of a register of all patients with HH admitted at two centers in Brazil. The first 20 eligible individuals among these patients diagnosed with axillary HH will be invited to take part in the trial, which will involve randomization to withdraw other HH treatments for 30 days. The baseline characteristics and the outcomes will be recorded using a Case Report Form (CRF).</p><p>The Brazilian Ministry of Health&#x02019;s National Research Ethics Commission (CONEP - Comiss&#x000e3;o Nacional de &#x000c9;tica em Pesquisa) approved the study protocol (CAAE 30283520.0.0000.5479; decision 3.978.439). The study will follow the protocol and will be entirely compliant with Helsinki Declaration ethical principles and the International Council for Harmonisation Guideline for Good Clinical Practice. The study protocol requires informed consent from each patient before any study procedures are initiated.</p><p>Clinical diagnoses will be made by a trained team member using standard clinical assessments; imaging is unnecessary. Patients will be considered eligible if they have a symptomatic HH score &#x02265; 52 on the QoL scale, have signed the informed consent form (ICF), responded to the HDSS, are aged from 18 to 45 years, and have no history of sympathectomy. The authors have listed detailed inclusion and exclusion criteria in <xref rid="t0100" ref-type="table">Table 1</xref>.</p><table-wrap position="float" id="t0100"><label>Table 1</label><caption><title>Inclusion and exclusion criteria for the TODAY clinical trial (topical oxybutynin for axillary hyperhidrosis).</title></caption><table frame="hsides" rules="groups"><col width="100%" span="1"/><thead><tr><th align="center" scope="col" style="border-top: solid 0.50pt; border-bottom: solid 0.50pt" valign="middle" rowspan="1" colspan="1">Inclusion criteria</th></tr></thead><tbody><tr><td align="left" style="border-top: solid 0.50pt" valign="middle" rowspan="1" colspan="1">1. Patients aged &#x02265; 18 years and &#x02264; 45 years</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">2. Patients who have not been treated with other medication or other treatment method therapeutic for the disease in the previous 30 days</td></tr><tr><td align="left" style="border-bottom: solid 0.50pt" valign="middle" rowspan="1" colspan="1">3. Quality of life (QOL) &#x02265; 52</td></tr><tr><td align="center" style="border-top: solid 0.50pt; border-bottom: solid 0.50pt" valign="middle" rowspan="1" colspan="1">Exclusion criteria</td></tr><tr><td align="left" style="border-top: solid 0.50pt" valign="middle" rowspan="1" colspan="1">1. Patients with hypersensitivity to oxybutynin hydrochloride</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">2. Patients who have been treated with other medication or other treatment method therapeutic for the disease in the previous 30 days</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">3. Patients with symptoms related to menopause</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">4. Patients with signs of skin changes in the axillary area</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">5. Pregnancy. Women with the potential to conceive and gestate who are not using contraceptive strategies and have not had a negative pregnancy test</td></tr><tr><td align="left" style="border-bottom: solid 0.50pt" valign="middle" rowspan="1" colspan="1">6. Patients with Covid in the contagious phase (PCR+)</td></tr></tbody></table></table-wrap></sec><sec><title>Randomization and intervention</title><sec><title>Randomization</title><p>Participants will be randomized into three treatment groups using a computer-generated randomization schedule prepared in advance of the study. In Group A, patients will be given oxybutynin at a dosage of 2.5 mg once a day, at night, for the first 7 days, followed by 2.5 mg twice a day from day 8 to day 21 and then 5 mg twice a day from day 22 to day 35. Group B will be given a topical placebo similar to the oxybutynin spray administered in two sprays into each armpit twice a day for 35 days. Group C will be given a topical oxybutynin 10% spray, also administered in two sprays into each armpit twice a day for 35 days.</p><p>Baseline characteristics will be recorded, and will be randomized electronically at a proportion of 1:1:1, balance with random sized blocks. This study will employ an open blinded endpoint design (<xref rid="gf0200" ref-type="fig">Figure 2</xref>).</p><fig position="float" fig-type="figure" id="gf0200"><label>Figure 2</label><caption><title>Flow diagram for the TODAY clinical trial (topical oxybutynin for axillary hyperhidrosis). QoL = quality of life; HH = hyperhidrosis; HDSS = Hyperhidrosis Disease Severity Scale.</title></caption><graphic xlink:href="jvb-24-e20240098-g02-en" position="float"/></fig><p>The REDCap validated software application will be used to generate a randomized list of variable sized blocks. In order to enroll a patient on the trial, the investigators will have to access the trial site and fill out a simple medical registration form.</p></sec><sec><title>Intervention</title><p>Patients will go through an initial screening at the first visit, followed by administration of two questionnaires: an HH-specific QoL form and the HDSS. Later, they will be randomized into one of three groups.</p><p>Both questionnaires, the QoL and the HDSS, will be administered at baseline and again on day 35, which is the last study visit.</p></sec></sec><sec><title>Quality of life questionnaire</title><p>To assess quality of life, each patient will answer a specific questionnaire<sup><xref rid="B015" ref-type="bibr">15</xref></sup> . The maximum score is 100 points. If a question is not applicable to a patient&#x02019;s situation or clinical condition, the authors will make proportional adjustments. The negative impact on QoL before treatment was classified into five satisfaction levels, calculated from the total score on the scale (varying from 20 to 100). A score greater than or equal to 84 indicates very bad QoL; scores from 68 to 83 indicate bad QoL; scores from 52 to 67 indicate good QoL; scores from 36 to 51 indicate very good QoL; and scores from 20 to 35 indicate excellent QoL. Improvements in QoL after treatment were also classified into five different levels. If the total score exceeded 84, QoL was considered much worse; from 68 to 83, slightly worse; from 52 to 67, unchanged; from 36 to 51, slightly better; and from 20 to 35, much better.</p></sec><sec><title>Hyperhidrosis disease severity scale</title><p>Patients assessed the severity of their sweating using the HDSS. Developed by the International Hyperhidrosis Society&#x000ae;, the HDSS was designed to be a rapid assessment tool that employs just one question with four possible responses. The responses measure the impact that HH has on the patient&#x02019;s daily life and their tolerance of the symptoms. The HDSS is simple, facilitating response and minimizing the likelihood of errors, thus optimizing the efficiency of medical assessments. This straightforward approach guarantees patients&#x02019; ability to rapidly and precisely convey the severity of their condition to healthcare providers. Varella et al.<sup><xref rid="B016" ref-type="bibr">16</xref></sup> translated the HDSS into Portuguese, guaranteeing its applicability and utility in Portuguese-speaking populations. The translation maintains the scale&#x02019;s integrity and efficacy, enabling consistent assessment of patients using different languages. The response options reflect the patient&#x02019;s tolerance of diaphoresis symptoms and the extent of the negative impact on their daily life. Level 1 indicates unnoticeable sweating that never interferes with daily activities; level 2 is tolerable sweating that sometimes interferes with daily activities; level 3 is barely tolerable sweating that frequently interferes with daily activities; and level 4 is intolerable sweating that always interferes with daily activities. Patients should assign a specific score for each area affected by HH. For data analysis, the authors calculate the improvement delta from the HDSS scores: HDSS before treatment (week 0) minus HDSS after treatment (at the follow-up visit) gives the delta. A delta of 0 indicates no improvement; a delta of 1 or 2 indicates slight improvement; and a delta of 3 is considered a significant improvement.</p></sec><sec><title>Primary efficacy endpoints</title><p>The endpoints for assessment of therapeutic efficacy will be improvement in HH severity up to day 35, measured by the HDSS [Time: day 35]. A treatment responder is defined as any participant whose initial HDSS score was 3 or 4 and who achieves an improvement of at least 1 point by day 35 and QoL will be assessed using improvement metrics from a quality of life questionnaire published in 2003.</p></sec><sec><title>Safety endpoints</title><p>Clinical assessment of adverse events and severe adverse events will be recorded as the number of participants who undergo adverse events, including dry mouth and cutaneous symptoms.</p></sec></sec><sec sec-type="discussion"><title>DISCUSSION</title><p>Hyperhidrosis is known as overactivity of sweat glands and is a common condition that predominantly affects young people during the maturation phase. The options for treatment of the condition are a subject of debate and axillary sprays containing oxybutynin have not been tested.</p><sec><title>Assessment of sweating</title><p>Devices that measure evaporation of sweat from the skin or the sweat can quantitatively assess diaphoresis. However, such instruments may not accurately reflect the daily discomfort undergone by individuals with HH. Therefore, patient-reported results are crucial to assess the impact of HH.<sup><xref rid="B017" ref-type="bibr">17</xref></sup> The HDSS and the QoL questionnaire objectively assess the progression of HH. QoL assessments are essential tools in medical research, because they enable collection of high-quality data for diagnosis and monitoring of patients&#x02019; results. The impact of HH on QoL is well-documented, with easy-to-use questionnaires that are essential for clinical assessments.</p></sec><sec><title>Impact on quality of life</title><p>The severity and location of HH can cause significant embarrassment, discomfort, and severe social, professional, and psychological problems, affecting daily activities and professional careers. Studies show that patients normally report bad or very bad QoL before treatment, because those whose QoL is better do not generally seek treatment. The main objective of HH treatment is to reduce production of sweat, which, when achieved, leads to improvements in QoL, relieving the psychological burden. These improvements are in spite of the potential side effects, generally considered insignificant by patients. In addition to impacting QoL, HH can also cause psychological and relational disorders, especially because it very often emerges during childhood and adolescence, which are critical periods for mental health development.</p></sec><sec><title>Psychological and social aspects</title><p>Anxiety disorders affect from 12.2% to 48.6% of the general population and frequently cause reduced QoL. These are chronic, recurrent, and heterogeneous disorders that are often related to poor general health and negative results. Previous studies have shown that people with HH often have higher anxiety levels, demonstrating the importance of covering psychosocial factors in management of these patients. Studies indicate that treatment of HH with oral anticholinergics achieves significant improvement in anxiety symptoms, probably because sweating is controlled. Anxiety and HH may share common paths related to an overactive autonomic nervous system; a type of intermittent dysautonomia. Patients with HH suffer from both the discomfort of excessive sweating and from fear of negative social judgment, leading to avoidance, social isolation, or hypervigilance.</p></sec><sec><title>Study expectations</title><p>We expect that the oxybutynin spray shows a trend to, at least, non-inferiority to oral oxybutynin and is superior to placebo in terms of efficacy.</p></sec><sec><title>Study limitations and future directions</title><p>This is the first study to investigate the impact of topical oxybutynin on QoL and HDSS scores. Limitations include the small sample size for a phase II trial and the impact of the COVID-19 pandemic, which restricted patient recruitment and access to HH diagnosis. After conclusion of the current phase II trial, future investigations will involve larger groups of patients treated with topical oxybutynin for prolonged periods and will include detection of oxybutynin in the blood using Liquid Chromatography-Mass Spectrometry (LC-MS), planned to understand the long-term results (<xref rid="gf0300" ref-type="fig">Figure 3</xref>).</p><fig position="float" fig-type="figure" id="gf0300"><label>Figure 3</label><caption><title>Timeline for the TODAY clinical trial (topical oxybutynin for axillary hyperhidrosis). CEP = Comit&#x000ea; de &#x000c9;tica em Pesquisa; CONEP = Comiss&#x000e3;o Nacional de &#x000c9;tica em Pesquisa.</title></caption><graphic xlink:href="jvb-24-e20240098-g03-en" position="float"/></fig></sec></sec><sec sec-type="conclusions"><title>CONCLUSIONS</title><p>The TODAY study is a phase II trial with a Prospective Randomized Open Blinded Endpoint (PROBE) design that will recruit patients diagnosed with axillary HH. The objective is to determine and assess the impact of topical oxybutynin on axillary HH. The study results will help guide medical decision-making with respect to the best way to manage axillary hyperhidrosis.</p></sec></body><back><fn-group><fn fn-type="other"><p><bold>How to cite:</bold> Neves S, Volpiani GG, Paganotti A, et al. Topical oxybutynin deodorant for axillary hyperhidrosis: a topic or a systemic effect? Rationale and design of the phase II today trial. J Vasc Bras. 2025;24:e20240098. <ext-link xlink:href="https://doi.org/10.1590/1677-5449.202400982" ext-link-type="uri">https://doi.org/10.1590/1677-5449.202400982</ext-link>
</p></fn><fn fn-type="financial-disclosure"><p>Financial support: None.</p></fn><fn fn-type="other"><p>The study was carried out at Irmandade da Santa Casa de Miseric&#x000f3;rdia de S&#x000e3;o Paulo, S&#x000e3;o Paulo, SP, Brazil.</p></fn></fn-group><bio id="d67e43"><p>Dermatologist, Brazilian Society of Dermatology; PhD in Health Sciences, Graduate Program, Irmandade Santa Casa de Miseric&#x000f3;rdia de S&#x000e3;o Paulo. </p></bio><bio id="d67e55"><p>Specialist in Vascular Surgery, SBACV; Specialist in Interventional Radiology and Endovascular Surgery, SOBRICE; Coordinator, Medical Residency Program in Vascular Surgery, Emergency and Urgent Care Team in Vascular Surgery. </p></bio><bio id="d67e66"><p>Medical Student, Faculty of Medical Sciences, Irmandade Santa Casa de Miseric&#x000f3;rdia de S&#x000e3;o Paulo; Observational Internship, Hemostasis and Thrombosis Research Laboratory, Loyola University Chicago.</p></bio><bio id="d67e77"><p>Medical Student, Faculty of Medical Sciences, Irmandade Santa Casa de Miseric&#x000f3;rdia de S&#x000e3;o Paulo.</p></bio><bio id="d67e88"><p>Specialist in Dermatology, Hospital Ipiranga; Specialist in Internal Medicine and Medical Clinic, Medical Residency Program, Faculty of Medicine, Funda&#x000e7;&#x000e3;o do ABC (FMABC); Medical Doctor, Faculty of Medicine, Funda&#x000e7;&#x000e3;o do ABC (FMABC).</p></bio><bio id="d67e99"><p>Doctor of Surgery Research, Faculty of Medical Sciences, Santa Casa de S&#x000e3;o Paulo; Adjunct Professor, Faculty of Medical Sciences, Santa Casa de S&#x000e3;o Paulo. </p></bio><bio id="d67e111"><p>Doctor in Surgery, Faculty of Medical Sciences, Santa Casa de S&#x000e3;o Paulo; Professor, Faculty of Medicine of Bahia, Federal University of Bahia (UFBA).</p></bio><bio id="d67e125"><p>Vascular Surgeon and Cardiovascular Scientist; Master, Paulista School of Medicine; Doctor, University of S&#x000e3;o Paulo.</p></bio><ref-list><title>REFERENCES</title><ref id="B001"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Nawrocki</surname><given-names>S</given-names></name>
<name><surname>Cha</surname><given-names>J</given-names></name>
</person-group><article-title>The etiology, diagnosis, and management of hyperhidrosis: a comprehensive review: etiology and clinical work-up</article-title><source>J Am Acad Dermatol</source><year>2019</year><volume>81</volume><issue>3</issue><fpage>657</fpage><lpage>666</lpage><pub-id pub-id-type="doi">10.1016/j.jaad.2018.12.071</pub-id><pub-id pub-id-type="pmid">30710604</pub-id>
</element-citation></ref><ref id="B002"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Schick</surname><given-names>CH</given-names></name>
</person-group><article-title>Pathophysiology of hyperhidrosis</article-title><source>Thorac Surg Clin</source><year>2016</year><volume>26</volume><issue>4</issue><fpage>389</fpage><lpage>393</lpage><pub-id pub-id-type="doi">10.1016/j.thorsurg.2016.06.002</pub-id><pub-id pub-id-type="pmid">27692196</pub-id>
</element-citation></ref><ref id="B003"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Sammons</surname><given-names>JE</given-names></name>
<name><surname>Khachemoune</surname><given-names>A</given-names></name>
</person-group><article-title>Axillary hyperhidrosis: a focused review</article-title><source>J Dermatolog Treat</source><year>2017</year><volume>28</volume><issue>7</issue><fpage>582</fpage><lpage>590</lpage><pub-id pub-id-type="doi">10.1080/09546634.2017.1309347</pub-id><pub-id pub-id-type="pmid">28318360</pub-id>
</element-citation></ref><ref id="B004"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Weber</surname><given-names>A</given-names></name>
<name><surname>Heger</surname><given-names>S</given-names></name>
<name><surname>Sinkgraven</surname><given-names>R</given-names></name>
<name><surname>Heckmann</surname><given-names>M</given-names></name>
<name><surname>Elsner</surname><given-names>P</given-names></name>
<name><surname>Rzany</surname><given-names>B</given-names></name>
</person-group><article-title>Psychosocial aspects of patients with focal hyperhidrosis. Marked reduction of social phobia, anxiety and depression and increased quality of life after treatment with botulinum toxin A</article-title><source>Br J Dermatol</source><year>2005</year><volume>152</volume><issue>2</issue><fpage>342</fpage><lpage>345</lpage><pub-id pub-id-type="doi">10.1111/j.1365-2133.2004.06334.x</pub-id><pub-id pub-id-type="pmid">15727649</pub-id>
</element-citation></ref><ref id="B005"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Wolosker</surname><given-names>N</given-names></name>
<name><surname>Campos</surname><given-names>JRM</given-names></name>
<name><surname>Kauffman</surname><given-names>P</given-names></name>
<etal>et al</etal>
</person-group><article-title>The use of oxybutynin for treating axillary hyperhidrosis</article-title><source>Ann Vasc Surg</source><year>2011</year><volume>25</volume><issue>8</issue><fpage>1057</fpage><lpage>1062</lpage><pub-id pub-id-type="doi">10.1016/j.avsg.2011.06.007</pub-id><pub-id pub-id-type="pmid">22023940</pub-id>
</element-citation></ref><ref id="B006"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Wolosker</surname><given-names>N</given-names></name>
<name><surname>Teivelis</surname><given-names>MP</given-names></name>
<name><surname>Krutman</surname><given-names>M</given-names></name>
<etal>et al</etal>
</person-group><article-title>Long-term results of the use of oxybutynin for the treatment of axillary hyperhidrosis</article-title><source>Ann Vasc Surg</source><year>2014</year><volume>28</volume><issue>5</issue><fpage>1106</fpage><lpage>1112</lpage><pub-id pub-id-type="doi">10.1016/j.avsg.2013.12.024</pub-id><pub-id pub-id-type="pmid">24512855</pub-id>
</element-citation></ref><ref id="B007"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Almeida</surname><given-names>ART</given-names></name>
<name><surname>Montagner</surname><given-names>S</given-names></name>
</person-group><article-title>Botulinum toxin for axillary hyperhidrosis</article-title><source>Dermatol Clin</source><year>2014</year><volume>32</volume><issue>4</issue><fpage>495</fpage><lpage>504</lpage><pub-id pub-id-type="doi">10.1016/j.det.2014.06.013</pub-id><pub-id pub-id-type="pmid">25152343</pub-id>
</element-citation></ref><ref id="B008"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Nawrocki</surname><given-names>S</given-names></name>
<name><surname>Cha</surname><given-names>J</given-names></name>
</person-group><article-title>Botulinum toxin: pharmacology and injectable administration for the treatment of primary hyperhidrosis</article-title><source>J Am Acad Dermatol</source><year>2020</year><volume>82</volume><issue>4</issue><fpage>969</fpage><lpage>979</lpage><pub-id pub-id-type="doi">10.1016/j.jaad.2019.11.042</pub-id><pub-id pub-id-type="pmid">31811879</pub-id>
</element-citation></ref><ref id="B009"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Du</surname><given-names>X</given-names></name>
<name><surname>Zhu</surname><given-names>X</given-names></name>
<name><surname>Wang</surname><given-names>T</given-names></name>
<etal>et al</etal>
</person-group><article-title>Compensatory hyperhidrosis after different surgeries at the same sympathetic levels: a meta-analysis</article-title><source>Ann Transl Med</source><year>2018</year><volume>6</volume><issue>11</issue><fpage>203</fpage><pub-id pub-id-type="doi">10.21037/atm.2018.05.24</pub-id><pub-id pub-id-type="pmid">30023366</pub-id>
</element-citation></ref><ref id="B010"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Wolosker</surname><given-names>N</given-names></name>
<name><surname>Kauffman</surname><given-names>P</given-names></name>
<name><surname>Campos</surname><given-names>JRM</given-names></name>
<etal>et al</etal>
</person-group><article-title>Long-term results of the treatment of primary hyperhidrosis with oxybutynin: follow-up of 1,658 cases</article-title><source>Int J Dermatol</source><year>2020</year><volume>59</volume><issue>6</issue><fpage>709</fpage><lpage>715</lpage><pub-id pub-id-type="doi">10.1111/ijd.14872</pub-id><pub-id pub-id-type="pmid">32301117</pub-id>
</element-citation></ref><ref id="B011"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Pariser</surname><given-names>DM</given-names></name>
<name><surname>Hebert</surname><given-names>AA</given-names></name>
<name><surname>Drew</surname><given-names>J</given-names></name>
<name><surname>Quiring</surname><given-names>J</given-names></name>
<name><surname>Gopalan</surname><given-names>R</given-names></name>
<name><surname>Glaser</surname><given-names>DA</given-names></name>
</person-group><article-title>Topical glycopyrroniumtosylate for the treatment of primary axillary hyperhidrosis: patient-reported outcomes from the ATMOS-1 and ATMOS-2 Phase III Randomized Controlled Trials</article-title><source>Am J Clin Dermatol</source><year>2019</year><volume>20</volume><issue>1</issue><fpage>135</fpage><lpage>145</lpage><pub-id pub-id-type="doi">10.1007/s40257-018-0395-0</pub-id><pub-id pub-id-type="pmid">30378087</pub-id>
</element-citation></ref><ref id="B012"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Abels</surname><given-names>C</given-names></name>
<name><surname>Soeberdt</surname><given-names>M</given-names></name>
<name><surname>Kilic</surname><given-names>A</given-names></name>
<etal>et al</etal>
</person-group><article-title>A glycopyrronium bromide 1% cream for topical treatment of primary axillary hyperhidrosis: efficacy and safety results from a phase IIIa randomized controlled trial</article-title><source>Br J Dermatol</source><year>2021</year><volume>185</volume><issue>2</issue><fpage>315</fpage><lpage>322</lpage><pub-id pub-id-type="doi">10.1111/bjd.19810</pub-id><pub-id pub-id-type="pmid">33445205</pub-id>
</element-citation></ref><ref id="B013"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Artzi</surname><given-names>O</given-names></name>
<name><surname>Loizides</surname><given-names>C</given-names></name>
<name><surname>Zur</surname><given-names>E</given-names></name>
<name><surname>Sprecher</surname><given-names>E</given-names></name>
</person-group><article-title>Topical oxybutynin 10% gel for the treatment of primary focal hyperhidrosis: a randomized double-blind placebo-controlled split area study</article-title><source>Acta Derm Venereol</source><year>2017</year><volume>97</volume><issue>9</issue><fpage>1120</fpage><lpage>1124</lpage><pub-id pub-id-type="doi">10.2340/00015555-2731</pub-id><pub-id pub-id-type="pmid">28654131</pub-id>
</element-citation></ref><ref id="B014"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Nguyen</surname><given-names>NV</given-names></name>
<name><surname>Gralla</surname><given-names>J</given-names></name>
<name><surname>Abbott</surname><given-names>J</given-names></name>
<name><surname>Bruckner</surname><given-names>AL</given-names></name>
</person-group><article-title>Oxybutynin 3% gel for the treatment of primary focal hyperhidrosis in adolescents and young adults</article-title><source>Pediatr Dermatol</source><year>2018</year><volume>35</volume><issue>2</issue><fpage>208</fpage><lpage>212</lpage><pub-id pub-id-type="doi">10.1111/pde.13404</pub-id><pub-id pub-id-type="pmid">29334132</pub-id>
</element-citation></ref><ref id="B015"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Campos</surname><given-names>JRM</given-names></name>
<name><surname>Kauffman</surname><given-names>P</given-names></name>
<name><surname>Werebe</surname><given-names>EC</given-names></name>
<etal>et al</etal>
</person-group><article-title>Quality of life, before and after thoracic sympathectomy: report on 378 operated patients</article-title><source>Ann Thorac Surg</source><year>2003</year><volume>76</volume><issue>3</issue><fpage>886</fpage><lpage>891</lpage><pub-id pub-id-type="doi">10.1016/S0003-4975(03)00895-6</pub-id><pub-id pub-id-type="pmid">12963223</pub-id>
</element-citation></ref><ref id="B016"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Varella</surname><given-names>AYM</given-names></name>
<name><surname>Fukuda</surname><given-names>JM</given-names></name>
<name><surname>Teivelis</surname><given-names>MP</given-names></name>
<etal>et al</etal>
</person-group><article-title>Translation and validation of Hyperhidrosis Disease Severity Scale</article-title><source>Rev Assoc Med Bras</source><year>2016</year><volume>62</volume><issue>9</issue><fpage>843</fpage><lpage>847</lpage><pub-id pub-id-type="doi">10.1590/1806-9282.62.09.843</pub-id><pub-id pub-id-type="pmid">28001258</pub-id>
</element-citation></ref><ref id="B017"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Sakiyama</surname><given-names>BYP</given-names></name>
<name><surname>Monteiro</surname><given-names>TV</given-names></name>
<name><surname>Ishy</surname><given-names>A</given-names></name>
<name><surname>Campos</surname><given-names>JRM</given-names></name>
<name><surname>Kauffman</surname><given-names>P</given-names></name>
<name><surname>Wolosker</surname><given-names>N</given-names></name>
</person-group><article-title>Quantitative assessment of the intensity of palmar and plantar sweating in patients with primary palmoplantar hyperhidrosis</article-title><source>J Bras Pneumol</source><year>2012</year><volume>38</volume><issue>5</issue><fpage>573</fpage><lpage>578</lpage><pub-id pub-id-type="doi">10.1590/S1806-37132012000500006</pub-id><pub-id pub-id-type="pmid">23147049</pub-id>
</element-citation></ref></ref-list></back><sub-article article-type="translation" id="S01" xml:lang="pt"><front-stub><article-id pub-id-type="publisher-id">jvbAR20240098_EN</article-id><article-id pub-id-type="doi">10.1590/1677-5449.202400981</article-id><article-categories><subj-group subj-group-type="heading"><subject>Protocolo De Estudo</subject></subj-group></article-categories><title-group><article-title>Desodorante t&#x000f3;pico de oxibutinina para hiperidrose axilar: efeito local ou sist&#x000ea;mico? Fundamenta&#x000e7;&#x000e3;o e desenho do estudo de fase II today</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0003-3272-2940</contrib-id><name><surname>Neves</surname><given-names>Samantha</given-names></name><role>concep&#x000e7;&#x000e3;o e desenho do estudo</role><role>an&#x000e1;lise e interpreta&#x000e7;&#x000e3;o dos dados</role><role>coleta de dados</role><role>reda&#x000e7;&#x000e3;o do artigo</role><role>aprova&#x000e7;&#x000e3;o final do artigo</role><role>an&#x000e1;lise estat&#x000ed;stica</role><role>responsabilidade geral do estudo</role><xref rid="aff01" ref-type="aff">1</xref><xref ref-type="bio" rid="d67e994">*</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0009-0001-1396-9553</contrib-id><name><surname>Volpiani</surname><given-names>Giuliano Giova</given-names></name><role>reda&#x000e7;&#x000e3;o do artigo</role><role>aprova&#x000e7;&#x000e3;o final do artigo</role><xref rid="aff01" ref-type="aff">1</xref><xref ref-type="bio" rid="d67e1006">*</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0003-2627-1821</contrib-id><name><surname>Paganotti</surname><given-names>Alexia</given-names></name><role>coleta de dados</role><xref rid="aff01" ref-type="aff">1</xref><xref ref-type="bio" rid="d67e1017">*</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0002-6978-2798</contrib-id><name><surname>Menegueti</surname><given-names>Felipe</given-names></name><role>coleta de dados</role><xref rid="aff01" ref-type="aff">1</xref><xref ref-type="bio" rid="d67e1028">*</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0009-0001-6008-589X</contrib-id><name><surname>Boix</surname><given-names>Ricardo Sanchez</given-names></name><role>coleta de dados</role><xref rid="aff01" ref-type="aff">1</xref><xref ref-type="bio" rid="d67e1039">*</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0001-6352-4408</contrib-id><name><surname>Caffaro</surname><given-names>Roberto Augusto</given-names></name><role>concep&#x000e7;&#x000e3;o e desenho do estudo</role><xref rid="aff01" ref-type="aff">1</xref><xref ref-type="bio" rid="d67e1050">*</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0003-2754-8618</contrib-id><name><surname>Santos</surname><given-names>Vanessa Prado dos</given-names></name><role>reda&#x000e7;&#x000e3;o do artigo</role><role>aprova&#x000e7;&#x000e3;o final do artigo</role><xref rid="aff02" ref-type="aff">2</xref><xref ref-type="bio" rid="d67e1062">*</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0002-5735-1333</contrib-id><name><surname>Ramacciotti</surname><given-names>Eduardo</given-names></name><role>concep&#x000e7;&#x000e3;o e desenho do estudo</role><role>an&#x000e1;lise e interpreta&#x000e7;&#x000e3;o dos dados</role><role>revis&#x000e3;o cr&#x000ed;tica do texto</role><role>aprova&#x000e7;&#x000e3;o final do artigo</role><xref rid="aff03" ref-type="aff">3</xref><xref rid="aff04" ref-type="aff">4</xref><xref ref-type="bio" rid="d67e1076">*</xref></contrib><aff id="aff01">
<label>1</label>
<institution content-type="original">Irmandade Santa Casa de Miseric&#x000f3;rdia de S&#x000e3;o Paulo, S&#x000e3;o Paulo, SP, Brasil.</institution>
</aff><aff id="aff02">
<label>2</label>
<institution content-type="original">Universidade Federal da Bahia, Faculdade de Medicina da Bahia, Salvador, BA, Brasil.</institution>
</aff><aff id="aff03">
<label>3</label>
<institution content-type="original">Science Valley Research Institute, S&#x000e3;o Paulo, SP, Brasil.</institution>
</aff><aff id="aff04">
<label>4</label>
<institution content-type="original">Loyola University Medical Center, Hemostasis &#x00026; Thrombosis Research Laboratories, Maywood, IL, EUA.</institution>
</aff></contrib-group><author-notes><fn fn-type="COI-statement"><p>Conflitos de interesse: Os autores declararam n&#x000e3;o haver conflitos de interesse que precisam ser informados.</p></fn><fn fn-type="other"><p>Aprova&#x000e7;&#x000e3;o do comit&#x000ea; de &#x000e9;tica: A Comiss&#x000e3;o Nacional de &#x000c9;tica em Pesquisa (CONEP) do Minist&#x000e9;rio da Sa&#x000fa;de do Brasil aprovou o protocolo do estudo (CAAE 30283520.0.0000.5479; parecer 3.978.439).</p></fn><corresp id="c01"><bold>Correspond&#x000ea;ncia</bold> Samantha Neves Irmandade Santa Casa de Miseric&#x000f3;rdia de S&#x000e3;o Paulo Rua Dr. Sodr&#x000e9;, 122, conjunto 41 - Vila Nova Concei&#x000e7;&#x000e3;o CEP 03545-110 - S&#x000e3;o Paulo (SP), Brasil Tel.: (11) 94524-0889 E-mail: <email>samanthaneves74@gmail.com</email>
</corresp></author-notes><permissions><copyright-statement>Copyright&#x000a9; 2025 Os autores.</copyright-statement><copyright-year>2025</copyright-year><copyright-holder>Os autores.</copyright-holder><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>Este &#x000e9; um artigo publicado em acesso aberto (Open Access) sob a licen&#x000e7;a Creative Commons Attribution, que permite uso, distribui&#x000e7;&#x000e3;o e reprodu&#x000e7;&#x000e3;o em qualquer meio, sem restri&#x000e7;&#x000f5;es desde que o trabalho original seja corretamente citado.</license-p></license></permissions><abstract><title>Resumo</title><p>Os anticolin&#x000e9;rgicos melhoram a qualidade de vida com redu&#x000e7;&#x000e3;o da sudorese em pacientes com hiperidrose, mas permanece incerto se a aplica&#x000e7;&#x000e3;o t&#x000f3;pica exerce efeitos locais ou sist&#x000ea;micos. O objetivo principal deste estudo &#x000e9; avaliar o impacto da oxibutinina t&#x000f3;pica na hiperidrose axilar. Vinte pacientes com hiperidrose axilar ser&#x000e3;o randomizados em tr&#x000ea;s grupos. O Grupo A receber&#x000e1; 2,5 mg de oxibutinina oral com diferentes posologias do primeiro ao 35&#x000ba; dia. O Grupo B receber&#x000e1; um placebo t&#x000f3;pico na forma de <italic toggle="yes">spray</italic>, e o Grupo C receber&#x000e1; um <italic toggle="yes">spray</italic> de oxibutinina a 10%, com duas borrifadas em cada axila duas vezes ao dia por 35 dias (produto em investiga&#x000e7;&#x000e3;o). O desfecho prim&#x000e1;rio ser&#x000e1; a avalia&#x000e7;&#x000e3;o da efic&#x000e1;cia do <italic toggle="yes">spray</italic> t&#x000f3;pico de oxibutinina, avaliada pelo n&#x000fa;mero de pacientes que apresentam melhora na gravidade da condi&#x000e7;&#x000e3;o. O estudo TODAY mostrar&#x000e1; evid&#x000ea;ncias sobre os efeitos da oxibutinina t&#x000f3;pica, avaliando seu impacto na hiperidrose axilar.</p></abstract><kwd-group><title>Palavras-chave: </title><kwd>hiperidrose</kwd><kwd>oxibutinina</kwd><kwd>anticolin&#x000e9;rgico</kwd><kwd>hiperidrose axilar</kwd></kwd-group></front-stub><body><sec sec-type="intro"><title>INTRODU&#x000c7;&#x000c3;O</title><p>A hiperidrose (HH) &#x000e9; uma condi&#x000e7;&#x000e3;o caracterizada por sudorese excessiva que vai al&#x000e9;m do necess&#x000e1;rio para regular a temperatura corporal<sup><xref rid="B001" ref-type="bibr">1</xref></sup> . Afeta aproximadamente 15,3 milh&#x000f5;es de indiv&#x000ed;duos na Am&#x000e9;rica do Norte<sup><xref rid="B002" ref-type="bibr">2</xref></sup> . A etiologia da HH prim&#x000e1;ria permanece mal definida, mas se acredita que envolva hiperatividade do sistema nervoso simp&#x000e1;tico devido a predisposi&#x000e7;&#x000f5;es gen&#x000e9;ticas<sup><xref rid="B003" ref-type="bibr">3</xref></sup> . A HH tem um impacto significativo na qualidade de vida (QoL) e est&#x000e1; associada a estigma social e profissional semelhante a condi&#x000e7;&#x000f5;es cr&#x000f4;nicas como psor&#x000ed;ase severa. Tamb&#x000e9;m h&#x000e1; taxas mais altas de depress&#x000e3;o e ansiedade relatadas entre indiv&#x000ed;duos com HH<sup><xref rid="B004" ref-type="bibr">4</xref></sup> . A HH prim&#x000e1;ria, tamb&#x000e9;m conhecida como idiop&#x000e1;tica, responde por cerca de 90% dos casos de HH, sendo a axila a &#x000e1;rea mais comumente afetada<sup><xref rid="B003" ref-type="bibr">3</xref></sup> . Essa forma de HH geralmente come&#x000e7;a na adolesc&#x000ea;ncia e tende a piorar com o passar dos anos<sup><xref rid="B005" ref-type="bibr">5</xref>-<xref rid="B007" ref-type="bibr">7</xref></sup> .</p><p>As op&#x000e7;&#x000f5;es de tratamento atuais para HH, incluindo simpatectomia toracosc&#x000f3;pica assistida por v&#x000ed;deo (VATS), inje&#x000e7;&#x000f5;es de toxina botul&#x000ed;nica, v&#x000e1;rias terapias t&#x000f3;picas e anticolin&#x000e9;rgicos orais, exibem efic&#x000e1;cia vari&#x000e1;vel e podem causar efeitos colaterais significativos<sup><xref rid="B008" ref-type="bibr">8</xref>,<xref rid="B009" ref-type="bibr">9</xref></sup> . Um estudo de longo prazo envolvendo 1.685 casos de HH prim&#x000e1;ria tratados com oxibutinina oral mostrou melhorias na qualidade de vida e diminui&#x000e7;&#x000e3;o da gravidade da HH, medida pela Escala de gravidade da doen&#x000e7;a da hiperidrose (HDSS), embora 24,9% dos pacientes tenham experimentado xerostomia severa<sup><xref rid="B010" ref-type="bibr">10</xref></sup> . Existem relatos limitados sobre anticolin&#x000e9;rgicos t&#x000f3;picos, e o glicopirrolato t&#x000f3;pico em forma de len&#x000e7;o e creme, bem como a oxibutinina em forma de gel, demonstraram ser eficazes<sup><xref rid="B011" ref-type="bibr">11</xref>-<xref rid="B014" ref-type="bibr">14</xref></sup> .</p></sec><sec><title>FUNDAMENTA&#x000c7;&#x000c3;O E OBJETIVOS DO ESTUDO</title><p>A avalia&#x000e7;&#x000e3;o do <italic toggle="yes">spray</italic> de oxibutinina t&#x000f3;pico, que &#x000e9; mais f&#x000e1;cil de usar, n&#x000e3;o foi testada anteriormente. O benef&#x000ed;cio de um <italic toggle="yes">spray</italic> de oxibutinina a 10% para HH axilar residiria em seus efeitos sist&#x000ea;micos limitados, o que pode reduzir os efeitos colaterais simpatomim&#x000e9;ticos observados com anticolin&#x000e9;rgicos orais e, potencialmente, melhorar a ades&#x000e3;o ao tratamento e melhorar tanto os escores de question&#x000e1;rio de QoL<sup><xref rid="B015" ref-type="bibr">15</xref></sup> quanto os escores de HDSS<sup><xref rid="B016" ref-type="bibr">16</xref></sup> .</p><p>Este estudo de fase II visa a avaliar a efic&#x000e1;cia de um <italic toggle="yes">spray</italic> t&#x000f3;pico de oxibutinina a 10% aplicado duas vezes ao dia em compara&#x000e7;&#x000e3;o com placebo e oxibutinina oral em pacientes com HH axilar.</p></sec><sec sec-type="methods"><title>M&#x000c9;TODOS</title><sec><title>Desenho do estudo</title><p>O TODAY (ClinicalTrials.gov: NCT05102396) &#x000e9; um estudo pragm&#x000e1;tico, randomizado, conduzido por investigadores acad&#x000ea;micos multic&#x000ea;ntricos. Ele vem do acr&#x000f4;nimo em ingl&#x000ea;s &#x0201c;<bold><italic toggle="yes"><underline>TO</underline></italic></bold>
<italic toggle="yes">pical oxybutynin for hyperhi</italic>
<bold><italic toggle="yes"><underline>D</underline></italic></bold>
<italic toggle="yes">rosis:</italic>
<bold><italic toggle="yes"><underline>A</underline></italic></bold>
<italic toggle="yes">topic or s</italic>
<bold><italic toggle="yes"><underline>Y</underline></italic></bold>
<italic toggle="yes">stemic effect</italic>&#x0201d;.</p><p>O estudo ser&#x000e1; aberto com avalia&#x000e7;&#x000e3;o de desfecho cega (PROBE, do acr&#x000f4;nimo em ingl&#x000ea;s <italic toggle="yes">Prospective Randomized Open Blinded Endpoint</italic>) e incluir&#x000e1; aproximadamente 21 pacientes em terapia anticolin&#x000e9;rgica com diagn&#x000f3;stico confirmado de HH, conforme ilustrado na <xref rid="gf01" ref-type="fig">Figura 1</xref>.</p><fig position="float" fig-type="figure" id="gf01"><label>Figura 1</label><caption><title>Desenho do estudo cl&#x000ed;nico TODAY (uso t&#x000f3;pico de oxibutinina para hiperidrose axilar).</title></caption><graphic xlink:href="jvb-24-e20240098-g01" position="float"/></fig><p>O estudo TODAY faz parte de um registro de todos os pacientes com HH admitidos em dois locais no Brasil. Desses pacientes, os primeiros 20 indiv&#x000ed;duos eleg&#x000ed;veis diagnosticados com HH axilar ser&#x000e3;o convidados a participar do ensaio, que envolve randomiza&#x000e7;&#x000e3;o para descontinua&#x000e7;&#x000e3;o de outros tratamentos para HH por 30 dias. As caracter&#x000ed;sticas basais e os desfechos ser&#x000e3;o registrados em um Formul&#x000e1;rio de Relato de Caso, o CRF (<italic toggle="yes">Case Report Form</italic>).</p><p>A Comiss&#x000e3;o Nacional de &#x000c9;tica em Pesquisa (CONEP) do Minist&#x000e9;rio da Sa&#x000fa;de do Brasil aprovou o protocolo do estudo (CAAE 30283520.0.0000.5479; parecer 3.978.439). O estudo cumprir&#x000e1; o protocolo e aderir&#x000e1; totalmente aos princ&#x000ed;pios &#x000e9;ticos da Declara&#x000e7;&#x000e3;o de Helsinki, especifica&#x000e7;&#x000f5;es do Conselho Internacional de Harmoniza&#x000e7;&#x000e3;o e Boas Pr&#x000e1;ticas Cl&#x000ed;nicas. O protocolo exige que cada paciente forne&#x000e7;a consentimento informado antes de iniciar qualquer procedimento do estudo.</p><p>O diagn&#x000f3;stico cl&#x000ed;nico ser&#x000e1; realizado por um membro da equipe treinado utilizando avalia&#x000e7;&#x000f5;es cl&#x000ed;nicas padr&#x000e3;o; a imagem n&#x000e3;o &#x000e9; necess&#x000e1;ria. Os pacientes ser&#x000e3;o considerados eleg&#x000ed;veis se apresentarem escore de HH sintom&#x000e1;tico &#x02265; 52 na QoL, tiverem assinado o formul&#x000e1;rio de consentimento informado (ICF), preenchido a HDSS, tiverem idade entre 18 e 45 anos e n&#x000e3;o tiverem hist&#x000f3;rico de simpatectomia. Os autores detalharam os crit&#x000e9;rios de inclus&#x000e3;o e exclus&#x000e3;o na <xref rid="t01" ref-type="table">Tabela 1</xref>.</p><table-wrap position="float" id="t01"><label>Tabela 1</label><caption><title>Crit&#x000e9;rios de inclus&#x000e3;o e exclus&#x000e3;o do estudo cl&#x000ed;nico TODAY (uso t&#x000f3;pico de oxibutinina para hiperidrose axilar).</title></caption><table frame="hsides" rules="groups"><col width="100%" span="1"/><thead><tr><th align="center" scope="col" style="border-top: solid 0.50pt; border-bottom: solid 0.50pt" valign="middle" rowspan="1" colspan="1">Crit&#x000e9;rios de inclus&#x000e3;o</th></tr></thead><tbody><tr><td align="left" style="border-top: solid 0.50pt" valign="middle" rowspan="1" colspan="1">1. Pacientes com idade &#x02265; 18 anos e &#x02264; 45 anos</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">2. Pacientes que n&#x000e3;o realizaram tratamento com outras medica&#x000e7;&#x000f5;es ou outro m&#x000e9;todo terap&#x000ea;utico para a doen&#x000e7;a nos &#x000fa;ltimos 30 dias</td></tr><tr><td align="left" style="border-bottom: solid 0.50pt" valign="middle" rowspan="1" colspan="1">3. Qualidade de vida (QOL) &#x02265; 52</td></tr><tr><td align="center" style="border-top: solid 0.50pt; border-bottom: solid 0.50pt" valign="middle" rowspan="1" colspan="1">Crit&#x000e9;rios de exclus&#x000e3;o</td></tr><tr><td align="left" style="border-top: solid 0.50pt" valign="middle" rowspan="1" colspan="1">1. Pacientes com hipersensibilidade a cloridrato de oxibutinina</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">2. Pacientes que realizaram tratamento com outras medica&#x000e7;&#x000f5;es ou outro m&#x000e9;todo terap&#x000ea;utico para a doen&#x000e7;a nos &#x000fa;ltimos 30 dias</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">3. Pacientes com sintomas relativos &#x000e0; menopausa</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">4. Pacientes com sinais de les&#x000f5;es de pele na regi&#x000e3;o axilar</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">5. Gravidez. Mulheres com potencial para concep&#x000e7;&#x000e3;o e gesta&#x000e7;&#x000e3;o sem uso de estrat&#x000e9;gias contraceptivas e sem realiza&#x000e7;&#x000e3;o do teste de gravidez negativo</td></tr><tr><td align="left" style="border-bottom: solid 0.50pt" valign="middle" rowspan="1" colspan="1">6. Pacientes com covid em fase de cont&#x000e1;gio (PCR+)</td></tr></tbody></table></table-wrap></sec><sec><title>Randomiza&#x000e7;&#x000e3;o e interven&#x000e7;&#x000e3;o</title><sec><title>Randomiza&#x000e7;&#x000e3;o</title><p>Os participantes ser&#x000e3;o randomizados em tr&#x000ea;s grupos de tratamento usando um cronograma de randomiza&#x000e7;&#x000e3;o gerado por computador preparado antes do estudo. No Grupo A, os pacientes receber&#x000e3;o oxibutinina na dosagem de 2,5 mg uma vez ao dia, &#x000e0; noite, durante os primeiros 7 dias, seguido de 2,5 mg duas vezes ao dia do dia 8&#x000ba; ao 21&#x000ba; e, ent&#x000e3;o, 5 mg duas vezes ao dia do dia 22&#x000ba; ao 35&#x000ba;. O Grupo B receber&#x000e1; um placebo t&#x000f3;pico como <italic toggle="yes">spray</italic> de oxibutinina aplicado com duas pulveriza&#x000e7;&#x000f5;es em cada axila duas vezes ao dia por 35 dias. O Grupo C receber&#x000e1; um <italic toggle="yes">spray</italic> t&#x000f3;pico de oxibutinina a 10%, tamb&#x000e9;m aplicado com duas pulveriza&#x000e7;&#x000f5;es em cada axila duas vezes ao dia por 35 dias.</p><p>Ser&#x000e3;o registradas as caracter&#x000ed;sticas basais, e ser&#x000e3;o randomizados eletronicamente usando uma propor&#x000e7;&#x000e3;o 1:1:1, equilibrando com blocos de tamanhos aleat&#x000f3;rios. Este estudo empregar&#x000e1; um desenho de desfecho cego aberto (<xref rid="gf02" ref-type="fig">Figura 2</xref>).</p><fig position="float" fig-type="figure" id="gf02"><label>Figura 2</label><caption><title>Fluxograma do estudo cl&#x000ed;nico TODAY (uso t&#x000f3;pico de oxibutinina para hiperidrose axilar). HH = hiperidrose; HDSS = Escala de gravidade da doen&#x000e7;a da hiperidrose; QoL = qualidade de vida.</title></caption><graphic xlink:href="jvb-24-e20240098-g02" position="float"/></fig><p>O <italic toggle="yes">software</italic> REDCap validado gerar&#x000e1; uma lista randomizada incorporando blocos de tamanhos vari&#x000e1;veis. Para inscrever um paciente no ensaio, os investigadores devem acessar o <italic toggle="yes">site</italic> do ensaio e completar um formul&#x000e1;rio de registro m&#x000e9;dico simples.</p></sec><sec><title>Interven&#x000e7;&#x000e3;o</title><p>Os pacientes passar&#x000e3;o por uma avalia&#x000e7;&#x000e3;o inicial de triagem durante a primeira visita, seguida por dois question&#x000e1;rios: um espec&#x000ed;fico de QoL para HH e uma HDSS. Subsequentemente, eles ser&#x000e3;o randomizados em um dos tr&#x000ea;s grupos.</p><p>Ambos os question&#x000e1;rios, QoL e HDSS, ser&#x000e3;o administrados na linha de base e novamente no 35&#x000ba; dia, que &#x000e9; a &#x000fa;ltima visita do estudo.</p></sec></sec><sec><title>Question&#x000e1;rio de qualidade de vida</title><p>Para avaliar a qualidade de vida, cada paciente completar&#x000e1; um question&#x000e1;rio espec&#x000ed;fico. Esse question&#x000e1;rio.<sup><xref rid="B015" ref-type="bibr">15</xref></sup> , consiste em uma pontua&#x000e7;&#x000e3;o m&#x000e1;xima de 100 pontos. Se uma pergunta n&#x000e3;o se aplicar &#x000e0; realidade espec&#x000ed;fica ou condi&#x000e7;&#x000e3;o cl&#x000ed;nica do paciente, os autores far&#x000e3;o ajustes proporcionais. O impacto negativo na QoL antes do tratamento foi classificado em cinco n&#x000ed;veis de satisfa&#x000e7;&#x000e3;o diferentes, calculados como a soma total da pontua&#x000e7;&#x000e3;o do protocolo (variando de 20 a 100). Uma pontua&#x000e7;&#x000e3;o igual ou maior que 84 indica uma QoL muito ruim; de 68 a 83 indica QoL ruim; de 52 a 67 indica QoL boa; de 36 a 51 indica QoL muito boa; e de 20 a 35 indica QoL excelente. A melhoria da QoL ap&#x000f3;s o tratamento tamb&#x000e9;m foi classificada em cinco n&#x000ed;veis de evolu&#x000e7;&#x000e3;o diferentes. Quando o total foi superior a 84, a QoL foi considerada muito pior; de 68 a 83, ligeiramente pior; de 52 a 67, igual; de 36 a 51, ligeiramente melhor; e de 20 a 35, muito melhor.</p></sec><sec><title>Escala de gravidade da doen&#x000e7;a de hiperidrose</title><p>Os pacientes usam a HDSS para avaliar a gravidade de sua sudorese. Desenvolvido pela International Hyperhidrosis Society&#x000ae;, a HDSS &#x000e9; projetada como uma ferramenta de avalia&#x000e7;&#x000e3;o r&#x000e1;pida, apresentando uma &#x000fa;nica pergunta com quatro poss&#x000ed;veis respostas. Essas respostas medem o impacto da HH na vida di&#x000e1;ria do paciente e a toler&#x000e2;ncia aos sintomas. A HDSS &#x000e9; simples, o que facilita a resposta e minimiza a probabilidade de erros, otimizando a efici&#x000ea;ncia das avalia&#x000e7;&#x000f5;es m&#x000e9;dicas. Essa abordagem direta garante que os pacientes possam transmitir rapidamente e com precis&#x000e3;o a gravidade de sua condi&#x000e7;&#x000e3;o aos provedores de sa&#x000fa;de. Varella et al.<sup><xref rid="B016" ref-type="bibr">16</xref></sup> traduziram a HDSS para o portugu&#x000ea;s, garantindo sua aplicabilidade e utilidade em popula&#x000e7;&#x000f5;es de l&#x000ed;ngua portuguesa. Essa tradu&#x000e7;&#x000e3;o mant&#x000e9;m a integridade e efic&#x000e1;cia da escala, permitindo avalia&#x000e7;&#x000f5;es consistentes dos pacientes em diferentes idiomas. Essas op&#x000e7;&#x000f5;es refletem a toler&#x000e2;ncia do paciente aos sintomas de sudorese e a extens&#x000e3;o do impacto negativo na vida di&#x000e1;ria. O grau 1 indica sudorese impercept&#x000ed;vel ou sem interfer&#x000ea;ncia na vida di&#x000e1;ria; o grau 2, sudorese toler&#x000e1;vel com interfer&#x000ea;ncia ocasional; o grau 3, sudorese moderadamente toler&#x000e1;vel com interfer&#x000ea;ncia frequente; e o grau 4, sudorese intoler&#x000e1;vel com interfer&#x000ea;ncia constante. Os pacientes devem atribuir uma pontua&#x000e7;&#x000e3;o espec&#x000ed;fica para cada local afetado pela HH. Para a an&#x000e1;lise de dados, os autores calculam um delta de melhoria a partir das pontua&#x000e7;&#x000f5;es da HDSS: HDSS antes do tratamento (semana 0) menos HDSS ap&#x000f3;s o tratamento (na visita de acompanhamento) igual ao delta. Um delta de 0 indica nenhuma melhoria; um delta de 1 ou 2 indica ligeira melhoria; e um delta de 3 &#x000e9; considerado uma melhoria significativa.</p></sec><sec><title>Resultados prim&#x000e1;rios de efic&#x000e1;cia</title><p>Os resultados para avalia&#x000e7;&#x000e3;o da efic&#x000e1;cia terap&#x000ea;utica ser&#x000e3;o a melhoria na gravidade da HH at&#x000e9; o dia 35, medida pela HDSS [Per&#x000ed;odo: dia 35]. Um respondedor ao tratamento &#x000e9; definido como qualquer participante cujo escore inicial da HDSS foi 3 ou 4 e que alcan&#x000e7;ou pelo menos uma melhoria de 1 ponto na escala at&#x000e9; o dia 35 e a avalia&#x000e7;&#x000e3;o da QoL usando m&#x000e9;tricas de melhoria de um question&#x000e1;rio de qualidade de vida publicado em 2003.</p></sec><sec><title>Resultados de seguran&#x000e7;a</title><p>A avalia&#x000e7;&#x000e3;o cl&#x000ed;nica de eventos adversos e eventos adversos graves foi registrada como o n&#x000fa;mero de participantes que experimentaram eventos adversos, incluindo boca seca e les&#x000f5;es cut&#x000e2;neas.</p></sec></sec><sec sec-type="discussion"><title>DISCUSS&#x000c3;O</title><p>A HH, conhecida como hiperfun&#x000e7;&#x000e3;o das gl&#x000e2;ndulas sudor&#x000ed;paras, &#x000e9; uma condi&#x000e7;&#x000e3;o comum que afeta predominantemente indiv&#x000ed;duos jovens durante sua fase de matura&#x000e7;&#x000e3;o. As op&#x000e7;&#x000f5;es de tratamento para essa condi&#x000e7;&#x000e3;o s&#x000e3;o um t&#x000f3;pico de debate, e os <italic toggle="yes">sprays</italic> axilares com oxibutinina n&#x000e3;o foram testados.</p><sec><title>Avalia&#x000e7;&#x000e3;o da sudorese</title><p>Dispositivos que medem a evapora&#x000e7;&#x000e3;o do suor da pele ou do suor podem avaliar quantitativamente a sudorese. No entanto, esses instrumentos podem n&#x000e3;o refletir com precis&#x000e3;o o desconforto di&#x000e1;rio experimentado por indiv&#x000ed;duos com HH. Assim, os resultados relatados pelos pacientes s&#x000e3;o cruciais para avaliar o impacto da HH<sup><xref rid="B017" ref-type="bibr">17</xref></sup> . A HDSS e a QoL avaliam a progress&#x000e3;o da HH objetivamente. As avalia&#x000e7;&#x000f5;es de QoL s&#x000e3;o ferramentas essenciais na pesquisa m&#x000e9;dica, pois permitem a coleta de dados de alta qualidade para o diagn&#x000f3;stico e monitoramento dos resultados dos pacientes. O impacto da HH na QoL &#x000e9; bem documentado, com question&#x000e1;rios f&#x000e1;ceis de usar e essenciais para as avalia&#x000e7;&#x000f5;es cl&#x000ed;nicas.</p></sec><sec><title>Impacto na qualidade de vida</title><p>A gravidade e localiza&#x000e7;&#x000e3;o da HH podem levar a um embara&#x000e7;o significativo, desconforto e graves problemas sociais, profissionais e psicol&#x000f3;gicos, afetando as atividades di&#x000e1;rias e as carreiras profissionais. Estudos mostraram que os pacientes normalmente relatam QoL ruim ou muito ruim antes do tratamento, pois aqueles com melhor QoL geralmente n&#x000e3;o procuram tratamento. O principal objetivo do tratamento da HH &#x000e9; reduzir a produ&#x000e7;&#x000e3;o de suor, o que, quando alcan&#x000e7;ado, leva a uma melhora na QoL, aliviando os fardos psicol&#x000f3;gicos. Essa melhoria ocorre apesar dos potenciais efeitos colaterais, geralmente considerados insignificantes pelos pacientes. Al&#x000e9;m de impactar a QoL, a HH tamb&#x000e9;m pode causar dist&#x000fa;rbios psicol&#x000f3;gicos e relacionais, especialmente porque, muitas vezes, aparece durante a inf&#x000e2;ncia e adolesc&#x000ea;ncia, um per&#x000ed;odo cr&#x000ed;tico para o desenvolvimento da sa&#x000fa;de mental.</p></sec><sec><title>Aspectos psicol&#x000f3;gicos e sociais</title><p>Transtornos de ansiedade, que afetam de 12,2% a 48,6% da popula&#x000e7;&#x000e3;o geral, frequentemente levam a uma redu&#x000e7;&#x000e3;o da QoL. S&#x000e3;o transtornos cr&#x000f4;nicos, recorrentes e heterog&#x000ea;neos, muitas vezes ligados &#x000e0; m&#x000e1; sa&#x000fa;de geral e a resultados negativos. Estudos anteriores mostraram que indiv&#x000ed;duos com HH frequentemente experimentam n&#x000ed;veis mais altos de ansiedade, destacando a import&#x000e2;ncia de abordar os fatores psicossociais no tratamento desses pacientes. Pesquisas indicam que o tratamento da HH com anticolin&#x000e9;rgicos orais leva a uma melhoria significativa nos sintomas de ansiedade, provavelmente devido &#x000e0; redu&#x000e7;&#x000e3;o da sudorese. Ansiedade e HH podem compartilhar caminhos comuns relacionados ao sistema nervoso aut&#x000f4;nomo hiperativo, um tipo de disautonomia intermitente. Pacientes com HH experimentam tanto o desconforto da sudorese excessiva quanto o medo do julgamento social negativo, levando a evita&#x000e7;&#x000e3;o, isolamento social ou hipervigil&#x000e2;ncia.</p></sec><sec><title>Expectativas do estudo</title><p>Esperamos que o <italic toggle="yes">spray</italic> de oxibutinina mostre uma tend&#x000ea;ncia de ser pelo menos n&#x000e3;o inferior &#x000e0; oxibutinina oral e superior ao placebo em termos de efic&#x000e1;cia.</p></sec><sec><title>Limita&#x000e7;&#x000f5;es do estudo e dire&#x000e7;&#x000f5;es futuras</title><p>Este estudo &#x000e9; o primeiro a investigar o impacto da oxibutinina t&#x000f3;pica nas pontua&#x000e7;&#x000f5;es de QoL e HDSS. As limita&#x000e7;&#x000f5;es incluem o pequeno tamanho da amostra para a fase II e o impacto da pandemia de covid-19, que restringiu o recrutamento de pacientes e o acesso ao diagn&#x000f3;stico de HH. Ap&#x000f3;s a conclus&#x000e3;o do atual estudo de fase II, pesquisas futuras envolver&#x000e3;o grupos de pacientes maiores tratados com oxibutinina t&#x000f3;pica por per&#x000ed;odos prolongados e incluir&#x000e3;o a detec&#x000e7;&#x000e3;o de oxibutinina no sangue usando LC-MS (<italic toggle="yes">Liquid Chromatography-Mass Spectometry</italic>, ou Cromatografia l&#x000ed;quida acoplada &#x000e0; espectrometria de massa) planejado para entender os resultados a longo prazo (<xref rid="gf03" ref-type="fig">Figura 3</xref>).</p><fig position="float" fig-type="figure" id="gf03"><label>Figura 3</label><caption><title>Linha do tempo do estudo cl&#x000ed;nico TODAY (uso t&#x000f3;pico de oxibutinina para hiperidrose axilar). CEP/CONEP = Comit&#x000ea;s de &#x000c9;tica em Pesquisa/Comiss&#x000e3;o Nacional de &#x000c9;tica em Pesquisa.</title></caption><graphic xlink:href="jvb-24-e20240098-g03" position="float"/></fig></sec></sec><sec sec-type="conclusions"><title>CONCLUS&#x000c3;O</title><p>O estudo TODAY &#x000e9; um ensaio cl&#x000ed;nico de fase II, prospectivo, randomizado e com desfecho aberto-cego (PROBE) em pacientes diagnosticados com HH axilar. O objetivo &#x000e9; determinar e avaliar o impacto da oxibutinina t&#x000f3;pica na HH axilar. Os resultados deste estudo ajudar&#x000e3;o a orientar a tomada de decis&#x000f5;es m&#x000e9;dicas em rela&#x000e7;&#x000e3;o &#x000e0; melhor gest&#x000e3;o da hiperidrose axilar.</p></sec></body><back><fn-group><fn fn-type="other"><p><bold>Como citar:</bold> Neves S, Volpiani GG, Paganotti A, et al. Desodorante t&#x000f3;pico de oxibutinina para hiperidrose axilar: efeito local ou sist&#x000ea;mico? Fundamenta&#x000e7;&#x000e3;o e desenho do estudo de fase II today. J Vasc Bras. 2025;24:e20240098. <ext-link xlink:href="https://doi.org/10.1590/1677-5449.202400981" ext-link-type="uri">https://doi.org/10.1590/1677-5449.202400981</ext-link>
</p></fn><fn fn-type="financial-disclosure"><p>Fonte de financiamento: Nenhuma.</p></fn><fn fn-type="other"><p>O estudo foi realizado na Irmandade da Santa Casa de Miseric&#x000f3;rdia de S&#x000e3;o Paulo, S&#x000e3;o Paulo, SP, Brasil.</p></fn></fn-group><bio id="d67e994"><p>M&#x000e9;dica Dermatologista, Sociedade Brasileira de Dermatologia; Doutora em Ci&#x000ea;ncias da Sa&#x000fa;de, P&#x000f3;s-gradua&#x000e7;&#x000e3;o, Irmandade Santa Casa de Miseric&#x000f3;rdia de S&#x000e3;o Paulo.</p></bio><bio id="d67e1006"><p>Especialista em Cirurgia Vascular, SBACV; Coordenador, Programa de Resid&#x000ea;ncia M&#x000e9;dica em Cirurgia Vascular, Equipe de Emerg&#x000ea;ncias e Urg&#x000ea;ncias em Cirurgia Vascular, Irmandade Santa Casa de Miseric&#x000f3;rdia de S&#x000e3;o Paulo.</p></bio><bio id="d67e1017"><p>Graduanda em Medicina, Faculdade de Ci&#x000ea;ncias M&#x000e9;dicas, Irmandade Santa Casa de Miseric&#x000f3;rdia de S&#x000e3;o Paulo; Est&#x000e1;gio Observacional, Laborat&#x000f3;rio de Pesquisa em Hemostasia e Trombose, Loyola University Chicago.</p></bio><bio id="d67e1028"><p>Graduando em Medicina, Faculdade de Ci&#x000ea;ncias M&#x000e9;dicas, Irmandade Santa Casa de Miseric&#x000f3;rdia de S&#x000e3;o Paulo.</p></bio><bio id="d67e1039"><p>Especialista em Dermatologia, Hospital Ipiranga; Especialista em Cl&#x000ed;nica M&#x000e9;dica e Medicina Interna, Programa de Resid&#x000ea;ncia M&#x000e9;dica, Faculdade de Medicina, Funda&#x000e7;&#x000e3;o do ABC (FMABC).</p></bio><bio id="d67e1050"><p>Doutor em Pesquisa em Cirurgia, Faculdade de Ci&#x000ea;ncias M&#x000e9;dicas, Santa Casa de S&#x000e3;o Paulo; Professor Adjunto, Faculdade de Ci&#x000ea;ncias M&#x000e9;dicas, Santa Casa de S&#x000e3;o Paulo.</p></bio><bio id="d67e1062"><p>Doutora em Cirurgia, Faculdade de Ci&#x000ea;ncias M&#x000e9;dicas, Santa Casa de S&#x000e3;o Paulo; Professora, Faculdade de Medicina da Bahia, Universidade Federal da Bahia (UFBA).</p></bio><bio id="d67e1076"><p>Cirurgi&#x000e3;o Vascular e Cientista na &#x000c1;rea Cardiovascular; Mestre, Escola Paulista de Medicina; Doutor, Universidade de S&#x000e3;o Paulo.</p></bio></back></sub-article></article>